Antiparasitic combination therapy

This page covers all Antiparasitic combination therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Leishmania cell membrane and ribosomal protein synthesis.

Targets

Leishmania cell membrane and ribosomal protein synthesis

Phase 3 pipeline (1)

• miltefosine + Paromomycin sulfate · Banaras Hindu University · Infectious Disease / Parasitology
  Miltefosine disrupts parasite cell membranes while paromomycin inhibits protein synthesis, together providing synergistic activity against Leishmania parasites.

Patent intelligence

• antiparasitic combination therapy patent landscape — aggregated cliff calendar, attackable patents, originator estates